0 46

Cited 1 times in

Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

 Kyong Joo Lee  ;  Jae Hee Cho  ;  Sang Hyub Lee  ;  Si Young Song  ;  Kwang Hyuk Lee  ;  Seok Jeong  ;  Ji Kon Ryu  ;  Sang Myung Woo  ;  Seungmin Bang  ;  Jong Kyun Lee  ;  Tae Hoon Lee  ;  Woo Hyun Paik  ;  Yong Tae Kim  ;  Woo Jin Lee 
 Cancer Chemotherapy and Pharmacology, Vol.80(4) : 799-805, 2017 
Journal Title
 Cancer Chemotherapy and Pharmacology 
Issue Date
Adult ; Aged ; Aged, 80 and over ; Anemia/chemically induced ; Anemia/epidemiology ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use* ; Disease-Free Survival ; Everolimus/adverse effects ; Everolimus/therapeutic use* ; Exanthema/chemically induced ; Exanthema/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local ; Pancreatic Neoplasms/drug therapy* ; Pancreatic Neoplasms/pathology ; Prognosis ; Republic of Korea ; Retrospective Studies ; Stomatitis/chemically induced ; Stomatitis/epidemiology ; Treatment Outcome ; Young Adult
Everolimus ; Pancreatic neuroendocrine tumor ; Prognosis ; Tumor grade ; World Health Organization classification
PURPOSE: Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs. METHODS: Tumors were graded according to the World Health Organization 2010 classification system. Patients with low or intermediate grade pNETs who received everolimus as first- or second-line chemotherapy between 2002 and 2014 were included. RESULTS: A total of 40 patients with metastatic or recurrent pNETs were included in this study. The median age was 54.5 years (range 19-83 years). Twelve patients (30%) experienced recurrence. There were 11 patients (27.5%) with low grade pNETs and 29 (72.5%) with intermediate. Everolimus was administered as first-line therapy in 30 patients (75%) and as second-line therapy in 10 patients (25%). The median progression-free survival (PFS) of patients with low and intermediate grade pNETs was significantly different (median not reached vs. 11 months, P = 0.015). On multivariate analysis, tumor grade (intermediate grade; HR 6.52, 95% CI 1.31-32.27, P = 0.022) was the only independent prognostic factor for PFS in pNETs. The most common adverse events were stomatitis, skin rash, and anemia. CONCLUSIONS: World Health Organization 2010 grade is the most important determinant for PFS in patients undergoing everolimus treatment for pNETs with an acceptable incidence of adverse events.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.